165 related articles for article (PubMed ID: 18953591)
1. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.
Li F; Xia W; Yuan S; Sun R
Pediatr Cardiol; 2009 Apr; 30(3):363-6. PubMed ID: 18953591
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.
Xiao JW; Zhu XY; Wang QG; Zhang DZ; Cui CS; Zhang P; Chen HY; Meng LL
Circ J; 2015; 79(6):1342-8. PubMed ID: 25797071
[TBL] [Abstract][Full Text] [Related]
3. The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension.
Ruan H; Zhang Y; Liu R; Yang X
Congenit Heart Dis; 2019 Jul; 14(4):645-650. PubMed ID: 31166081
[TBL] [Abstract][Full Text] [Related]
4. Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
Hanson SFL; Terry MH; Moretta DT; Power GG; Wilson SM; Alam F; Ahsan F; Blood AB; Giri PC
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):472-480. PubMed ID: 29756460
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats.
Li FH; Xia W; Li AW; Zhao CF; Sun RP
Chin Med J (Engl); 2007 Jan; 120(1):22-9. PubMed ID: 17254483
[TBL] [Abstract][Full Text] [Related]
6. [Acute effects of intravenous fasudil with different dosage on patients with congenital heart defects and severe pulmonary arterial hypertension].
Ruan HY; Zhang YG; Liu R
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(9):678-681. PubMed ID: 29534403
[No Abstract] [Full Text] [Related]
7. Effects of the Rho-kinase inhibitor, fasudil, on pulmonary hypertension.
Odagiri K; Watanabe H
Circ J; 2015; 79(6):1213-4. PubMed ID: 25925979
[No Abstract] [Full Text] [Related]
8. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.
Fujita H; Fukumoto Y; Saji K; Sugimura K; Demachi J; Nawata J; Shimokawa H
Heart Vessels; 2010 Mar; 25(2):144-9. PubMed ID: 20339976
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Dai ZK; Wu BN; Chen IC; Chai CY; Wu JR; Chou SH; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2011 Jan; 46(1):45-59. PubMed ID: 20717937
[TBL] [Abstract][Full Text] [Related]
10. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension.
Ishikura K; Yamada N; Ito M; Ota S; Nakamura M; Isaka N; Nakano T
Circ J; 2006 Feb; 70(2):174-8. PubMed ID: 16434811
[TBL] [Abstract][Full Text] [Related]
11. Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study.
Zhang X; Zhang X; Wang S; Luo J; Zhao Z; Zheng C; Shen J
Can Respir J; 2018; 2018():3148259. PubMed ID: 29785232
[TBL] [Abstract][Full Text] [Related]
12. Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study.
Jiang X; Wang YF; Zhao QH; Jiang R; Wu Y; Peng FH; Xu XQ; Wang L; He J; Jing ZC
Int J Cardiol; 2014 Nov; 177(1):61-5. PubMed ID: 25499341
[TBL] [Abstract][Full Text] [Related]
13. Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat.
Badejo AM; Dhaliwal JS; Casey DB; Gallen TB; Greco AJ; Kadowitz PJ
Am J Physiol Lung Cell Mol Physiol; 2008 Nov; 295(5):L828-36. PubMed ID: 18689606
[TBL] [Abstract][Full Text] [Related]
14. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
[TBL] [Abstract][Full Text] [Related]
15. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats.
Li F; Xia W; Li A; Zhao C; Sun R
Pharmacol Res; 2007 Jan; 55(1):64-71. PubMed ID: 17127075
[TBL] [Abstract][Full Text] [Related]
16. The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study.
Jasińska-Stroschein M; Owczarek J; Łuczak A; Orszulak-Michalak D
Pharmacology; 2013; 91(3-4):178-84. PubMed ID: 23428587
[TBL] [Abstract][Full Text] [Related]
17. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.
Fukumoto Y; Matoba T; Ito A; Tanaka H; Kishi T; Hayashidani S; Abe K; Takeshita A; Shimokawa H
Heart; 2005 Mar; 91(3):391-2. PubMed ID: 15710736
[No Abstract] [Full Text] [Related]
18. Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene.
Yasuda T; Tada Y; Tanabe N; Tatsumi K; West J
Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L667-74. PubMed ID: 21856816
[TBL] [Abstract][Full Text] [Related]
19. Effects of fasudil on pulmonary hypertension in clinical practice.
Zhang Y; Wu S
Pulm Pharmacol Ther; 2017 Oct; 46():54-63. PubMed ID: 28782712
[TBL] [Abstract][Full Text] [Related]
20. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
Jiang BH; Tawara S; Abe K; Takaki A; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Feb; 49(2):85-9. PubMed ID: 17312448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
